Vivani Medical Inc

Vivani Medical Inc has a strong liquidity position, with a current ratio of 4.55, indicating that the company has more than four times as many current assets as current liabilities. The company holds $24.9 million in cash and equivalents, which is a significant portion of its total assets of $48.2 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. The price-to-book ratio is 4.34, indicating that the market is valuing the company at a premium to its book value. The company is currently unprofitable, with a net loss of $5.36 million and an operating loss of $5.68 million. Its return on equity is -22.48%, and its return on assets is -11.11%, both of which are negative and significantly below the industry median for medical equipment and supplies companies. The company's operating cash flow is negative at -$9.31 million, and its free cash flow is -$5.29 million, indicating that it is not generating positive cash flow from operations. Vivani Medical Inc does not disclose segment or geographic revenue data in the provided financials, so it is not possible to assess revenue concentration or geographic exposure. The company's capital expenditures are relatively low at -$219,000, suggesting minimal investment in new assets. The company's growth trajectory is unclear due to the lack of historical revenue data, but the current financials indicate a need for significant operational improvements to achieve profitability. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has no long-term debt and a strong cash position, which reduces its exposure to liquidity risk. The dilution risk is also low, as the company has not issued additional shares recently, and there are no signs of dilution pressure in the near term. There are no recent filings or transcripts provided in the data to assess recent events or strategic developments. The company's market price is $1.20, and the mean price target from analysts is $4.83, suggesting a potential upside of 302.5%. However, the company's current financial performance and lack of profitability may limit its ability to meet these price targets in the near term.